We are live on ! Find out more
PBA

Paradigm Biocapital Advisors Portfolio holdings

AUM $4.89B
1-Year Est. Return 251.12%
This Fund
S&P 500
This Quarter Est. Return
-11.56%
1 Year Est. Return
+251.12%
3 Year Est. Return
+670.11%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.18B
AUM Growth
-$691M
Cap. Flow
-$226M
Cap. Flow %
-10.34%
Top 10 Hldgs %
76.03%
Holding
34
New
6
Increased
11
Reduced
10
Closed
6

Top Buys

Rank Stock Value
1
MRUS
Merus
MRUS
+$73.2M
2
CYTK icon
Cytokinetics
CYTK
+$39.5M
3
INSM icon
Insmed
INSM
+$34.5M
4
MTSR
Metsera Inc
MTSR
+$33.8M
5
COGT icon
Cogent Biosciences
COGT
+$31.7M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$266M
2
VERA icon
Vera Therapeutics
VERA
+$60.8M
3
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$49.3M
4
PLRX icon
Pliant Therapeutics
PLRX
+$42.1M
5
TECX
Tectonic Therapeutic
TECX
+$22.4M

Sector Composition

Rank Sector Weight
1 Healthcare 99.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EWTX icon
26
CALL
Edgewise Therapeutics
EWTX
$4.86B
$11M 0.5%
+500,000
New +$13.1M
OCUL icon
27
Ocular Therapeutix
OCUL
$1.89B
$9.63M 0.44%
+1,314,018
New +$10.1M
IMTX icon
28
Immatics
IMTX
$1.31B
$8.6M 0.39%
1,907,108
-3,507,301
-65% -$18.3M
AGIO icon
29
Agios Pharmaceuticals
AGIO
$1.89B
– –
-276,439
Closed -$9.08M
PLRX icon
30
Pliant Therapeutics
PLRX
$65M
– –
-3,197,050
Closed -$42.1M
SRRK icon
31
Scholar Rock
SRRK
$5.68B
– –
-400,000
Closed -$17.3M
VERA icon
32
Vera Therapeutics
VERA
$2.17B
– –
-1,437,339
Closed -$60.8M
TECX
33
Tectonic Therapeutic
TECX
$561M
– –
-485,105
Closed -$22.4M
ORKA
34
Oruka Therapeutics
ORKA
$5.85B
– –
-819,660
Closed -$15.9M
1
2

Similar funds

KCM
Kensico Capital Management Greenwich, Connecticut $4.9B AUM 41.26% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
FC
Freemont Capital Singapore $4.91B AUM 5.45% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return
MCCA
Mill Creek Capital Advisors Conshohocken, Pennsylvania $4.87B AUM 17.69% 1-Year Est. Return
SIA
Sit Investment Associates Minneapolis, Minnesota $4.93B AUM 12.22% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
SMFG
Sumitomo Mitsui Financial Group Tokyo, Japan $4.94B AUM 1.39% 1-Year Est. Return

Paradigm Biocapital Advisors's Q1 2025 Portfolio in Review

As of Q1 2025, Paradigm Biocapital Advisors held 34 positions worth $2.18B, down 24% from $2.87B the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Paradigm Biocapital Advisors withdrew a net $226M in Q1 2025, closing 6 positions and reducing 10 holdings. Its most notable exit was Vera Therapeutics, an estimated $60.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier.

Against the trend, Paradigm Biocapital Advisors opened a new position in Cytokinetics worth $34.5M.

  • Paradigm Biocapital Advisors's largest Q1 2025 buy was Cytokinetics: 858,664 shares worth $34.5M.
  • Paradigm Biocapital Advisors added most to Merus in Q1 2025, an estimated $73.2M increase.
  • Paradigm Biocapital Advisors's biggest Q1 2025 reduction was argenx, cutting an estimated $266M.
  • Paradigm Biocapital Advisors fully exited Vera Therapeutics in Q1 2025, selling an estimated $60.8M.
  • Paradigm Biocapital Advisors's ten largest holdings make up 76% of its $2.18B portfolio in Q1 2025.
  • Paradigm Biocapital Advisors opened 6 new positions and closed 6 in Q1 2025.
  • Paradigm Biocapital Advisors's portfolio value fell 24% quarter-over-quarter to $2.18B.

Based on Paradigm Biocapital Advisors's 13F filing for Q1 2025, filed 15 May 2025.